drugset / Trial / NCT00017342

Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia

NCT00017342

Open-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining bryostatin 1 with cytarabine in treating patients who have relapsed primary acute myelogenous leukemia.

Timeline

Start
2001-07
Primary completion
2004-09
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Cytarabine Small molecule Intravenous
Subject bryostatin 1 Small molecule Intravenous

Indications